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ABSTRACT The aim of this study was to evaluate the protective efﬁcacy of MTBK_
24820, a complete form of PPE39 protein derived from a predominant Beijing/K strain of
Mycobacterium tuberculosis in South Korea. Mice were immunized with MTKB_24820, M.
bovis Bacilli Calmette-Guérin (BCG), or adjuvant prior to a high-dosed Beijing/K strain
aerosol infection. After 4 and 9 weeks, bacterial loads were determined and histopatho-
logic and immunologic features in the lungs and spleens of the M. tuberculosis-infected
mice were analyzed. Putative immunogenic T-cell epitopes were examined using syn-
thetic overlapping peptides. Successful immunization of MTBK_24820 in mice was con-
ﬁrmed by increased IgG responses (P  0.05) and recalled gamma interferon (IFN-),
interleukin-2 (IL-2), IL-6, and IL-17 responses (P  0.05 or P  0.01) to MTBK_24820. Af-
ter challenge with the Beijing/K strain, an approximately 0.5 to 1.0 log10 reduction in
CFU in lungs and fewer lung inﬂammation lesions were observed in MTBK_24820-
immunized mice compared to those for control mice. Moreover, MTBK_24820 immuniza-
tion elicited signiﬁcantly higher numbers of CD4 T cells producing protective cytokines,
such as IFN- and IL-17, in lungs and spleens (P  0.01) and CD4 multifunctional T
cells producing IFN-, tumor necrosis factor alpha (TNF-), and/or IL-17 (P  0.01) than
in control mice, suggesting protection comparable to that of BCG against the hyperviru-
lent Beijing/K strain. The dominant immunogenic T-cell epitopes that induced IFN- pro-
duction were at the N terminus (amino acids 85 to 102 and 217 to 234). Its vaccine po-
tential, along with protective immune responses in vivo, may be informative for vaccine
development, particularly in regions where the M. tuberculosis Beijing/K-strain is fre-
quently isolated from TB patients.
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Tuberculosis (TB) is caused by infection with Mycobacterium tuberculosis. TB is amajor global health problem, with approximately 10.4 million new cases and 1.4
million deaths worldwide in 2015 (1). Approximately 58% of new cases were reported
in Southeast Asia and Western Paciﬁc regions, including China and South Korea (1). The
Beijing strain is prevalent in China and surrounding countries, including South Korea
(2). The Beijing strain also has been associated with TB outbreaks in North America (3)
and multidrug resistance in New York City in the United States (4, 5).
Bacilli Calmette-Guérin (BCG), the most widely used vaccine against TB, has variable
protective efﬁcacy, from 0 to 80% (6, 7), and shows low levels of protection against the
modern Beijing lineage strain (8). The Beijing strain induces extensive pneumonia in
mice and results in earlier mortality compared toM. tuberculosis H37Rv infection in spite
of prior BCG vaccination (8). In a human study, the Beijing genotype occurs more
frequently in Vietnamese patients with a BCG scar than in those without it (9).
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Therefore, the vaccine candidates should be able to protect from prevalent and
hypervirulent M. tuberculosis strains in preclinical testing.
In South Korea, TB remains a major public health concern, with an incidence of 80
cases per 100,000 people (10). More than 80% of clinical isolates from Korean pulmo-
nary TB patients belong to the Beijing genotype (11, 12, 13). Beijing/K strains were
identiﬁed as the major cause of pulmonary TB outbreaks (14) and were associated with
drug resistance (13) in South Korea. The Beijing/K strain has rapid replication with more
severe pathologies at early times after infection compared to M. tuberculosis H37Rv in
mice (15, 16).
From a whole-genome sequence analysis of the Beijing/K strain, we identiﬁed
MTBK_24820 (GenBank accession no. AIB49026.1) within the 5.7-kb insertion region
compared with the genome of H37Rv strain (17). In the inserted region, ESAT-6 like (esx)
proteins, such as InsB (MTBK_24790) and InsC (MTBK_24800) (18, 19), and PPE proteins,
including InsD (MTBK_24810; partial form of PPE38) and MTBK_24820 (N-terminally
added PPE39 protein), are inserted in a row. Unlike other PE-PPE proteins located in a
row in the ESX region (20), MTBK_24820 exists independently, without PE proteins in
the insertion region. MTBK_24820 is a PPE-MTPR subfamily with repeats of NxGxGNxG
in the C terminus (17, 21) and is orthologous to theM. tuberculosis H37Rv PPE39 protein
(annotated Rv2353c) (22). PPE39 has a number of highly genetic variables among
several M. tuberculosis isolates, caused by IS6110 integration and the addition of
single-nucleotide polymorphisms (SNPs) (23). PPE39 of H37Rv strain is truncated at the
N terminus, whereas MTBK_24820 of Beijing/K strain includes 259 additional amino
acids at the N terminus, which is deﬁned as a complete form of PPE39 in this study (see
Fig. S1 in the supplemental material). There is also a PPE39 homologue in M. bovis BCG
Pasteur 1173P2 strain with genetic variation, including SNPs in the N-terminal region,
and about 150 amino acids in the C terminus are fused with part of PPE40 (23).
Our previous microarray experiments showed an approximately 8.1-fold overexpres-
sion of MTBK_24820 in the Beijing/K strain compared with PPE39 in the H37Rv strain.
Sequence analysis of MTBK_24820 showed six transmembrane helices with no signal
peptide and the N terminus oriented towards the inside of the cell (TMpred software
[http://embnet.vital-it.ch/software/TMPRED_form.html] and SignalP 4.1 server [http://
www.cbs.dtu.dk/services/SignalP/]). However, the function of PPE39 has not yet been
proved.
Some PE/PPE proteins play a role in mycobacterial pathogenesis linked to bacterial
growth in host macrophages or macrophage maturation processes. For example,
PE_PGRS33 and PPE38 inhibited phagocytosis of M. tuberculosis (24, 25), and deletion
of PPE25 in M. avium induces inhibition of phagolysosomal fusion (26). PE4-expressing
M. smegmatis showed improved survival in murine macrophages (27). ppe18 knockout
M. tuberculosis-infected mice decreased bacterial burden and showed less tissue dam-
age, suggesting that PPE18 plays a role in survival of M. tuberculosis (28). In addition,
PE/PPE family proteins have highly immunogenic T-cell epitopes that induce secretion
of gamma interferon (IFN-) (29, 30). A multiepitope DNA vaccine, including peptides
derived from PE19 and PPE25, induces potent IFN- responses (31).
Based on sequence analyses and the overexpression of MTBK_24820 in the Beijing/K
strain, we hypothesized that the complete form of PPE39 has protective efﬁcacy against
M. tuberculosis infection, particularly in mice infected with the hypervirulent clinical
isolate Beijing/K. We assessed the performance of immunization with MTBK_24820
compared to that with BCG following challenge with the Beijing/K strain in mice. The
bacterial loads, histopathology, and cytokine signatures in lungs and spleens of the
mice were examined at 4 and 9 weeks postinfection. In addition, the immunogenic
T-cell epitopes of MTBK_24820 necessary to elicit IFN- production were determined.
RESULTS
MTBK_24820-induced immune responses in mice. Successful immunization of
mice with MTBK_24820 was conﬁrmed by MTBK_24820-speciﬁc IgG responses. Mice
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immunized with MTBK_24820 had signiﬁcantly higher MTBK_24820-speciﬁc IgG re-
sponses than mice immunized with adjuvant or BCG (P  0.01) (Fig. 1A).
To determine the immunogenicity of MTBK_24820, expression of 10 cytokines,
including Th1 and Th2 cytokines, was examined in the lungs and spleens of mice
immunized with MTBK_24820. Among the cytokines tested, IFN-, interleukin-2 (IL-2),
IL-6, and IL-17 production was signiﬁcantly increased in a dose-dependent manner in
mice immunized with MTBK_24820 (P  0.05 for IFN- and P  0.01 for IL-2, IL-6, and
IL-17) (Fig. 1B). Despite the presence of PPE39 homologue in M. bovis BCG, none of the
cytokines were detected in the mice immunized with BCG. Th2 cytokines, such as IL-4
and IL-5, were not detected in any groups (data not shown).
MTBK_24820-induced protective efﬁcacy against TB. To evaluate the protective
properties of MTBK_24820, the immunized mice were challenged with the Beijing/K
strain of M. tuberculosis and bacterial counts were assessed in the lungs and spleens.
The MTBK_24820-immunized group showed an approximately 0.5-log reduction in CFU
in the lungs at 4 weeks postinfection (P  0.05), and it was nearly the same level of
protection as that seen in the BCG-immunized group (P  0.01) (Fig. 2A). At 9 weeks
postinfection, the CFU reduction in MTBK_24820-immunized mice was still signiﬁcant
compared with the level for the control group (P  0.01) (Fig. 2A), although the CFU
reduction had fallen to 0.2 log. In spleens, MTBK_24820-immunized mice showed
superior protection over the control group (P 0.05), whereas BCG did not signiﬁcantly
lower the bacterial loads at 9 weeks postinfection (Fig. 2B).
The protective efﬁcacy of MTBK_24820 against TB infection was also examined by
histopathology. At 4 weeks postinfection, the calculated percentage of inﬂammation
lesions was higher in control mice immunized with adjuvant (19.4 to 27.5%) than in
FIG 1 MTBK_24820-speciﬁc immune responses in C56BL/6 mice immunized with adjuvant, M. bovis BCG, or MTBK_24820.
(A) Three weeks after the last immunization with adjuvant alone, BCG, or MTBK_24820, the IgG antibodies speciﬁc to
MTBK_24820 were measured in sera. OD, optical density; adjuvant, DDA and MPL. (B) MTBK_24820-speciﬁc recall responses
induced by immunization were measured in spleen cell culture supernatants after stimulation with 0, 0.1, 1, or 10 g/ml
of MTBK_24820 prior to M. tuberculosis Beijing/K strain aerosol infection. Concentrations of IL-2, IL-6, IFN-, and IL-17 were
determined using multiplex bead assays. Data are presented as means SD for duplicate determinations from three mice.
Signiﬁcant differences between groups were analyzed by one-way ANOVA (*, P  0.05; **, P  0.01).
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mice immunized with BCG (5.4 to 12.9%) (P  0.01) or MTBK_24820 (9.1 to 16.4%) (P 
0.01) (Fig. 2C). At 9 weeks postchallenge, the inﬂammation of the lesions was more
severe than at 4 weeks, but the BCG-immunized mice (20.0 to 24.3%) (P  0.01) and
MTBK_24820-immunized mice (17.5 to 28.2%) (P  0.01) still showed fewer inﬂamma-
tion lesions than the control mice (35.1 to 39.4%) (Fig. 2D). There was no signiﬁcant
difference in inﬂammation lesion areas between BCG- and MTBK_24820-immunized
mice (Fig. 2D). These results indicate that MTBK_24820 had protective efﬁcacy against
the virulent Beijing/K strain.
FIG 2 Protective efﬁcacy of immunization with MTBK_24820 in mice against the M. tuberculosis Beijing/K strain. Three weeks after the ﬁnal
immunization, mice were challenged with 1,000 CFU of virulent Beijing/K strain. At 4 and 9 weeks postinfection, all mice were sacriﬁced and
bacterial burden (CFU) was measured from homogenized lungs (A) and spleens (B). Dots represent the mean log10 values obtained for individually
tested animals, and lines represent the means  SD from ﬁve mice. For histopathologic analysis of the lungs from immunized mice, mice were
sacriﬁced at 4 (C) and 9 (D) weeks postinfection. The lung sections were stained with H&E (20 magniﬁcation; bar, 200 m). The percentage of
inﬂammation lesions was calculated using 10 magniﬁcation ﬁelds and ImageJ software. Signiﬁcant differences between multiple groups were
conﬁrmed by one-way ANOVA (*, P  0.05; **, P  0.01).
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MTBK_24820-induced cellular immune responses in mice infected with the
Beijing/K strain of M. tuberculosis. To assess whether the Beijing/K strain of M.
tuberculosis could recall immune responses that were induced by previous immu-
nization with MTBK_24820, cytokine responses were measured in the lungs and
spleens. The production of IL-2, IL-6, IFN-, and IL-17 in response to MTBK_24820
immunization was maintained after the infection with Beijing/K strain (Fig. 3).
MTBK_24820-immunized mice showed signiﬁcantly higher concentrations of IL-2,
IL-6, IFN-, and IL-17 production in both the lungs and spleens at 4 and 9 weeks
postinfection compared to those of the adjuvant group (P  0.01 in all cases) (Fig.
3). IFN- production in MTBK_24820-immunized mice was elevated even more at 9
weeks postinfection than at 4 weeks postinfection (P  0.01) (Fig. 3C). On the
contrary, the IL-2, IL-6, and IL-17 responses of the MTBK_24820-immunized mice
were decreased at 9 weeks postinfection in the lungs (P  0.01) (Fig. 3A, B, and D).
We next examined T cells producing IFN- and IL-17 in response to MTBK_24820.
Mice immunized with MTBK_24820 had a higher proportion of CD4 T cells producing
IFN- than did the mice with adjuvant alone (P  0.01) (Fig. 4A and B). Similarly, the
percentage of CD4 T cells producing IL-17 in MTBK_24820-immunized mice was
higher than that in the adjuvant group (P  0.01) (Fig. 4C and D). The proportion of
CD8 T cells producing IFN- or IL-17 in response to MTBK_24820 was also signiﬁcantly
FIG 3 Cytokine production in the lungs and spleens from M. tuberculosis Beijing/K-infected mice following ex vivo
stimulation with MTBK_24820. Concentrations of protection-related cytokines to MTBK_24820 (5 g/ml) were
determined ex vivo at 4 and 9 weeks postinfection. Concentrations of IL-2 (A), IL-6 (B), IFN- (C), and IL-17 (D) in
cell culture supernatants were measured. Data are presented as means SD from ﬁve mice. Signiﬁcant differences
between multiple groups were analyzed by unpaired t tests (**, P  0.01).
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higher in MTBK_24820-immunized mice than in the adjuvant group (P 0.01) (data not
shown). These results suggest that MTBK_24820 generates MTBK_24820-speciﬁc Th1
and Th17 cytokine responses that could be maintained during delayed infections,
which may play a role in protection against TB.
MTBK_24820 immunization induced antigen-speciﬁc multifunctional T cells in
Beijing/K-infected mice. Based on reports showing the association between multi-
functional T cells and protection against TB in mice (32, 33), the existence of multi-
functional CD4 T cells was examined in mice immunized with MTBK_24820. In
response to MTBK_24820 immunization, CD4 T cells producing IFN-, TNF-, and IL-17
were observed in lung and spleen cells from MTBK_24820-immunized mice (Fig. 5).
Double-positive CD4 T cells producing IFN- and TNF-, IFN- and IL-17, or TNF- and
IL-17 were identiﬁed at 4 and 9 weeks postinfection (Fig. 5). MTBK_24820 immunization
also induced triple-positive CD4 T cells, although the proportion of triple-positive
CD4 T cells producing IFN-, TNF-, and IL-17 was lower than that of double-positive
CD4 T cells (P  0.01 for Fig. 5A, B, and C and P  0.05 for Fig. 5D). BCG-immunized
mice did not produce IL-17 but were limited to IFN- and TNF- production in the lungs
(Fig. 5A and B). IFN--producing CD8 T cells were observed in all groups, whereas
none of the mice produced multifunctional CD8 T cells (data not shown). These results
indicate that MTBK_24820 induces multifunctional T-cell responses to the Beijing/K
strain of M. tuberculosis, and these responses may be involved in protection against TB.
FIG 4 CD4 T cells producing protection-related cytokines in the lungs and spleens of M. tuberculosis
Beijing/K-infected mice in response to MTBK_24820. At 4 and 9 weeks postinfection, cells from the lungs
and spleens were stimulated with MTBK_24820 (5 g/ml) for 24 h, and the percentage of IFN--positive
CD4 T cells in the lungs (A) and spleens (B) and IL-17-positive CD4 T cells in the lungs (C) and spleens
(D) were determined. Data are presented as means  SD from two independent experiments with ﬁve
mice. Signiﬁcant differences between multiple groups were analyzed by unpaired t tests (**, P  0.01).
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The dominant epitope of MTBK_24820 in T cells of Beijing/K-infected mice. To
determine potential epitopes of MTBK_24820, the IFN- responses to synthetic pep-
tides that overlapped within the N terminus of MTBK_24820 were examined in spleen
cells from the Beijing/K strain-challenged mice at 4 and 9 weeks postinfection. The
dominant epitopes were at amino acids 85 to 102 (AFEAARAAMVDPVVVAAN) at the
early stage of infection and amino acids 217 to 234 (GSGNIGNTNLGGGNIGSF), with
increased IFN-, at 9 weeks postinfection (Fig. 6). However, IFN- secretion in response
to the peptides was not observed in naive C57BL/6- and M. tuberculosis H37Rv-infected
mice (data not shown). These data indicate that the N terminus of MTBK_24820 has
potent T-cell epitopes that contribute to protection against TB speciﬁcally caused by
the Beijing/K strain.
DISCUSSION
Evidence so far indicates that MTBK_24820 has protective efﬁcacy and induces
strong Th1 and IL-17 responses against M. tuberculosis Beijing/K infection in mice
immunized with MTBK_24820. Several reports have suggested that IFN- and IL-17
production by CD4 T cells is targeted in vaccine-induced immunity to M. tuber-
culosis infection in mouse models (34, 35). The immunogenic IFN--generating
T-cell epitopes in PE/PPE family proteins are potential TB vaccines (30) and diag-
nostic biomarkers (36). In this study, two predominant epitope sites were demon-
strated by strong IFN--inducing T cells at amino acids 85 to 102 and 217 to 234.
FIG 5 Functional proﬁles of MTBK_24820-speciﬁc CD4 T cells based on IFN-, TNF-, and IL-17 production. Multifunc-
tional CD4 T cells in the lungs and spleens from each group of immunized mice were analyzed by ﬂow cytometry. At 4
and 9 weeks postinfection, cells were stimulated with MTBK_24820 (5 g/ml) for 12 h in the presence of GolgiPlug. The
percentage of IFN--, F--, and/or IL-17-producing CD4 T cells in the lungs (A and B) and spleens (C and D) are
presented as means  SD from two independent experiments with ﬁve mice. Signiﬁcant differences compared to the
adjuvant control group were analyzed by unpaired t tests (*, P  0.05; **, P  0.01).
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An additional 3 potential epitope sites with weak IFN- responses were also
observed at the C terminus of MTBK_24820 (data not shown) that were absent from
M. bovis BCG. Therefore, the insufﬁcient immune responses to MTBK_24820 in mice
immunized with BCG likely are due to the genetic variation at the C terminus
between the two strains.
IL-17 is a proinﬂammatory cytokine that induces neutrophil recruitment, which may
result in protection against TB (37). Mice with genetically inactivated IL-17A receptor
failed to control bacterial burden, resulting in accelerated mortality in long-term
infections even though the bacterial burden was controlled during the acute phase of
M. tuberculosis infection (38). Moreover, the IL-17 requirement for host protection
against TB depends on the M. tuberculosis strain in mice. IL-17 contributes to early
protection by inducing CXCL-13, which is required for T-cell localization within lung
lymphoid follicles in response to hypervirulent M. tuberculosis HN878 infection, while
IL-17 does not impact protective immunity against laboratory-adapted M. tuberculosis
H37Rv infection (39). Our data demonstrated that high levels of IL-17 production were
induced in the lungs of MTBK_24820-immunized mice at early phases of infection and
may function in the control of bacterial burden during the course of M. tuberculosis
Beijing/K infection.
There are now TB vaccine candidates containing PPE genes in clinical trial phase II
trials. The ID93 vaccine candidate, sponsored by IDRI, has PPE42 (40). This vaccine has
decreased bacterial loads and elicited CD4 and CD8 multifunctional T-cell responses
in mice infected with multidrug-resistant TN5904 as well as H37Rv (41). Mtb72F,
developed by GSK, contains PPE18, which was produced from the H37Rv strain (40, 42).
Several genetic variations, including SNPs in PPE18, have been observed in clinical
isolates and result in alteration of amino acid sequences even in T-cell epitopes (43).
This means that Mtb72F may have limitations as a vaccine to recognize some M.
tuberculosis strains attributable to antigenic variation. A vaccine composed of PPE
genes, conversely, may be valuable due to the cross-reactivity with many PPE homo-
logues throughout theM. tuberculosis genome (44). In contrast to the genetic variations
of the PPE genes, according to BLAST analyses, better than 99% homology for
MTBK_24820 was found in other clinical isolates, namely, the M. tuberculosis Haarlem
family, which caused a higher frequency of multidrug-resistant TB (45), and CDC1551,
which was highly transmissible and virulent in humans (46). This suggests that
MTBK_24820 is a vaccine candidate that can protect against otherM. tuberculosis strains
as well as Beijing/K.
Although the protective efﬁcacy of MTBK_24820, determined by CFU counting and
FIG 6 IFN- responses induced by MTBK_24820 overlapping peptides in M. tuberculosis Beijing/K-
infected mice. At 4 and 9 weeks postinfection, splenocytes were stimulated with control medium (RPMI),
ConA (1 g/ml), or 10 g/ml of the synthetic peptides covering the N terminus of MTBK_24820 for 48
h for measurement of the IFN- responses in cell culture supernatants. Peptides spanning the amino
acids of MTBK_24820 at the N terminus are shown on the x axis, and dotted boxes represent peptides
that induced IFN- responses. Data are presented as means  SD from two independent experiments
with four mice.
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histological pathology, was not signiﬁcantly different from that of BCG in mice, the
efﬁcacy of MTBK_24820 seems to be longer lasting than that of BCG based on the CFU
counts. Meanwhile, the protective immune responses were signiﬁcantly higher in mice
immunized with MTBK_24820 than in those immunized with BCG, which suggests that
BCG has methods other than the pathways releasing the cytokines in response to
MTBK_24820 for protection against M. tuberculosis Beijing/K infection. We also deter-
mined bacterial loads and histopathological features in mice challenged with the
Erdman strain. We observed an approximately 0.5 to 1.0 log10 reduction of CFU in lungs
and fewer lung inﬂammation lesions in MTBK_24820-immunized mice at 4 and 10
weeks postinfection compared with the control mice (adjuvant only or BCG vaccinated).
Compared with mice with the Beijing/K strain, Erdman-challenged mice showed higher
reduction of bacterial loads by MTBK_24820 immunization, and the protective efﬁcacy
of MTBK_24820 was better than that of BCG at 10 weeks postinfection (see Fig. S2 in
the supplemental material). Considering the high prevalence of the Beijing/K strain of
M. tuberculosis and the relatively poor protection of BCG against the W-Beijing geno-
type of M. tuberculosis (8, 47), it would be worthwhile to test MTBK_24820 derived from
the strain as a vaccine candidate, particularly in an area where TB is endemic. The
dominant epitope sites of the T cells observed in MTBK_24820 also exist in M. bovis
BCG, but the subdominant epitope sites were not found in M. bovis BCG. Therefore, it
is necessary to evaluate the protective efﬁcacy of MTBK_24820 using the potential
epitopes in mice infected with the Beijing/K strain. These further studies may give a clue
to the scarce immune responses observed in mice immunized with BCG in this study.
The persistence of protective efﬁcacy and the response of multifunctional T cells in
mice immunized with MTBK_24820 also should be conﬁrmed at least 9 weeks postin-
fection or later.
Taken together, MTBK_24820, a complete form of PPE39, showed protective efﬁcacy
against infection with the Beijing/K strain. The protective efﬁcacy and strong immune
responses of MTBK_24820 may give helpful information for development of new
vaccines in areas where TB is endemic. MTBK_24820 could be used as an antigen for
improved future vaccines against the highly transmissible and virulent M. tuberculosis
strains, including Beijing/K.
MATERIALS AND METHODS
Animals. All mouse experiments were in accordance with guidelines and used animal protocols
(permit number 2013-0089) approved by the Institutional Animal Care and Use Committee, Yonsei
University College of Medicine (Seoul, South Korea). C57BL/6N (female, 5 to 6 weeks of age) mice were
purchased from SLC, Inc. (Shijuoka, Japan), and maintained in the animal biosafety level 3 facility at the
Yonsei University College of Medicine.
Preparation and puriﬁcation of recombinant MTBK_24820 antigen. MTBK_24820 from the Bei-
jing/K strain was cloned into pYUB1062, which contains six histidine tags at the C terminus, with NdeI
and HindIII (New England BioLabs, Ipswich, MA, USA) digestion (48). The MTBK_24820 gene was
ampliﬁed using the following primers from M. tuberculosis Beijing/K strain genomic DNA: MTBK_24820F,
5=-TACATATGGTGGTGAATTTTTCGGTGTTG-3=, including the underlined NdeI site, and MTBK_24820R,
5=-CCAAAGCTTTCCGAACAAGTTCTTGAAGA-3=, including the underlined HindIII site. The constructed
plasmid was transformed into Escherichia coli BL21(DE3), and the strain containing MTBK_24820 was
cultured in LB medium containing 150 g/ml hygromycin (A.G. Scientiﬁc, Inc., San Diego, CA, USA) at
37°C until the optical density at 600 nm (OD600) reached 0.6 to 0.7. Overexpression of MTBK_24820 was
carried out by addition of 1 mM IPTG (isopropyl--D-thiogalactopyranoside; Bio-World, Dublin, OH, USA)
and puriﬁed using nickel-nitrilotriacetic acid (Ni-NTA) agarose resin (Qiagen, Venlo, Netherlands). Further
puriﬁcation was conducted using MonoQ anion exchange columns on an ÄKTA fast protein liquid
chromatography system (GE Healthcare Biosciences, Pittsburgh, PA, USA) (see Fig. S3A in the supple-
mental material). The ﬁnal puriﬁed product was conﬁrmed by SDS-PAGE analysis (Fig. S3A). Bicinchoninic
acid (BCA) assays (Thermo Fisher Scientiﬁc, Inc., Rockford, IL, USA) were used to measure protein
concentrations. Samples were sterilized by gamma radiation and stored at 80°C until use.
Mycobacterial strains. The M. bovis BCG Pasteur 1173P2 strain was kindly provided by the Pasteur
Institute (Paris, France). The M. tuberculosis Beijing/K strain was obtained from the Korean Institute of
Tuberculosis (KIT; Osong, Chungchungbukdo, South Korea). All strains were grown in Middlebrook 7H9
broth (Difco Laboratories, Detroit, MI, USA) supplemented with 10% oleic acid-albumin-dextrose-catalase
(OADC; Becton Dickinson, Sparks, MD, USA) and 0.02% glycerol for 4 weeks at 37°C. Single-cell suspen-
sions of each strain were prepared as previously described (16). The concentrations of each lot of both
strains were determined by plating serial dilutions on Middlebrook 7H11 agar (Difco Laboratories)
supplemented with OADC (Becton Dickinson). Aliquots of each strain were stored at 80°C until use.
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Immunization and infection. Mice were immunized by subcutaneous injection with 20 g of
MTBK_24820 protein. The protein was emulsiﬁed in dimethyl dioctadecyl ammonium bromide (DDA; 250
g/dose; Sigma-Aldrich, St. Louis, MO, USA) and monophospholipid A (MPL; 25 g/dose; Sigma-Aldrich).
Injections were given three times at 3-week intervals. Phosphate-buffered saline (PBS) emulsiﬁed with
DDA and MPL was used for the sham-immunized group (49). BCG (2  105 CFU/dose), as a control
vaccine, was subcutaneously injected into mice once 6 weeks before the Beijing/K infection. Three weeks
after the ﬁnal immunization, sera and spleens from three mice of each group were obtained for
MTBK_24820-induced immune response analysis.
Mice were challenged with approximately 1,000 CFU of the Beijing/K strain using an aerosol
apparatus (Glas-Col, Terre Haute, IN, USA) 3 weeks after the ﬁnal immunization. The initial dose was
conﬁrmed the following day. The protective efﬁcacy was evaluated using CFU counts at 4 and 9 weeks
postinfection.
Determination of bacterial load and histopathologic analysis. To estimate the numbers of viable
bacteria in the lungs and spleens of infected mice, tissues were removed aseptically at designated times
and homogenized in 2 ml of PBS. Tenfold serial dilutions of each homogenate were plated onto
Middlebrook 7H11 agar plates supplemented with OADC containing amphotericin B (Sigma-Aldrich).
Plates were incubated for 28 days at 37°C and then bacterial colonies were counted.
For histopathologic analysis of the lungs, the right posterior lobes were collected and ﬁxed in 10%
formaldehyde buffer. Samples were cut into 5-m-thick slices and stained with hematoxylin and eosin
(H&E) for microscopic analysis (Olympus, Tokyo, Japan). Lung inﬂammation lesions relative to the area of
the total visual ﬁeld were evaluated by ImageJ software (National Institutes of Health, Bethesda, MD,
USA). Results are represented as the percentage of area with lesions.
Preparation of lung and spleen cells. The lungs and spleens were removed from immunized and/or
infected mice. The lung tissue was chopped and incubated in RPMI medium (Welgene, Daejeon, South
Korea) containing collagenase type II (Worthington Biochemical Co., Lakewood, NJ, USA) for 30 min at
37°C and passed through a 40-m cell strainer (BD Biosciences, San Jose, CA, USA). Spleen cells were
isolated by passing through a mesh strainer. Red blood cells were lysed using ACK lysis buffer (0.15 M
NH4Cl, 1 mM KHCO3, and 0.1 mM Na2EDTA). Cells were washed and resuspended in RPMI medium
containing 10% fetal bovine serum and 1 U/ml antibiotic-antimycotic (Invitrogen, Grand Island, NY, USA).
Cells were stimulated with 0.1, 1, or 5 g/ml of MTBK_24820 for 24 h at 37°C for determination of
cytokine responses. For the intracellular cytokine staining, cells were stimulated with 5 g/ml of
MTBK_24820 for 24 h at 37°C.
Intracellular cytokine staining. The isolated lung or spleen cells were stimulated with 5 g/ml of
MTBK_24820 for 12 h at 37°C in the presence of GolgiPlug (BD Biosciences). Cells were stained with
peridinin chlorophyll protein (PerCP)-Cy5.5-conjugated anti-CD4, allophycocyanin (APC)-Cy7-conjugated
anti-CD8, and ﬂuorescein isothiocyanate (FITC)-conjugated anti-CD44 antibodies (eBioscience, Vienna,
Austria) for 30 min at 4°C. Cells were ﬁxed and permeabilized using a Cytoﬁx/Cytoperm kit (BD
Biosciences) and stained with phycoerythrin (PE)-conjugated anti-IFN-, 	PC-conjugated anti-TNF-, and
PE-Cy7-conjugated anti-IL-17 (eBioscience). All analyses were performed using a FACSVerse ﬂow cytom-
eter (BD Biosciences). Acquired data were analyzed using FlowJo 10.0 software (FlowJo, LLC, Ashland, OR,
USA). The gating strategy for multifunctional T-cell populations is represented in Fig. S4.
Quantiﬁcation of IgG antibodies speciﬁc to MTBK_24820. Blood samples were collected from the
mice 3 weeks after the ﬁnal immunization. Sera were separated after clotting of whole blood at room
temperature, followed by centrifugation at 1,500  g for 15 min and storage at 20°C until use. To
determine the level of the anti-IgG antibodies in response to MTBK_24820, anti-IgG enzyme-linked
immunosorbent assays (ELISAs) were performed as previously described (18). Brieﬂy, 5 g/ml
MTBK_24820 was diluted in 0.5 M carbonate-bicarbonate buffer and coated onto 96-well plates (Corning
Inc., Oneonta, NY, USA) for 16 h at 4°C. Wells were blocked with PBS containing 5% normal goat serum
(NGS). Serum samples were diluted 1:1,000 and added to the wells. After 1 h at 37°C, peroxidase-
conjugated anti-mouse IgG antibody (1:10,000 dilution; Merck, Darmstadt, Germany) was added and
incubated for 1 h at 37°C. Reactions within the plates were visualized using tetramethylbenzidine
substrate (KPL, Gaithersburg, MD, USA) and stopped with 2.5 N H2SO4. Absorbance was read at 450 nm
using a VersaMax ELISA reader (Molecular Devices, Sunnyvale, CA, USA).
Multiplex bead array. Concentrations of IL-2, IL-6, IFN-, and IL-17 from the lung and spleen cell
culture supernatants stimulated with MTBK_24820 were simultaneously measured using FlowCytomix
(BMS820FF; eBioscience) according to the manufacturer’s protocol. Standard curves for each analyte
were obtained by the best ﬁt of the data points using FlowCytomix Pro software (eBioscience), and values
outside the standard curve were adjusted by setting the minimum and maximum values.
Design of synthetic MTBK_24820 peptides and IFN- ELISAs. A total of 21 peptides which overlap
by six amino acids were synthesized for determination of potential epitope sites (GenScript, Piscataway,
NJ, USA) (Fig. S3B). The overlapping peptides span 259 amino acids at the N terminus of MTBK_24820.
Peptides were diluted in RPMI medium at 1 mg/ml and stored at 20°C until use. Spleen cells from
infected mice were stimulated with 10 g/ml of each peptide or 1 g/ml of concanavalin A (ConA)
(Sigma-Aldrich). After incubation for 24 h at 37°C, cell culture supernatants were harvested and IFN-
responses were detected using ELISAs (eBioscience) according to the manufacturer’s protocol.
Statistical analysis. Data were analyzed using Prism 6.0 software (GraphPad, La Jolla, CA, USA). Mean
values and standard deviations (SD) were calculated for each experimental group. Differences among the
adjuvant-alone, M. bovis BCG, and MTBK_24820 groups were compared using one-way analysis of
variance (ANOVA) followed by Dunn’s multiple-comparison tests or two-tailed unpaired t tests. P values
of 0.05 (*), 0.01 (**), and 0.001 (***) were considered signiﬁcant.
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